Jefferies upgraded NASDAQ:PTGX to a "Buy" rating, with the stock priced at $97.78.The FDA has approved ICOTYDE™, a significant milestone for Protagonist Therapeutics, triggering a $50 million milestone payment.Despite the positive news, PTGX's stock price slightly decreased by 0.14% to $97.09.Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a biopharmaceutical company focused on developing peptide-based drugs to address unmet medical needs. The company operates in the competitive pharmaceutical industry, wh ...